We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina and Genpathway Announce Partnership to Provide Whole-Genome ChIP-Sequencing Services
News

Illumina and Genpathway Announce Partnership to Provide Whole-Genome ChIP-Sequencing Services

Illumina and Genpathway Announce Partnership to Provide Whole-Genome ChIP-Sequencing Services
News

Illumina and Genpathway Announce Partnership to Provide Whole-Genome ChIP-Sequencing Services

Read time:
 

Illumina, Inc. and Genpathway have announced the formation of a partnership to provide researchers whole-genome chromatin immunoprecipitation (ChIP) sequencing services. Samples are first prepared using Genpathway’s FactorPath ChIP assays, and then sequenced by the Genome Analyzer through Illumina’s Sequencing Services.

Final data analysis is completed by Genpathway using their proprietary software analysis tools. Combined, the Illumina and Genpathway services provide researchers with access to a complete ChIP-sequencing solution for identifying and quantifying transcription factor binding sites across the entire genome.

Specifically, the combined services include cell or tissue processing, antibody selection and qualification, ChIP using Genpathway’s optimized procedures for greater sensitivity and specificity, ChIP DNA amplification, quality-control steps throughout the assay, Sequencing Services using Illumina’s Genome Analyzer, and complete data analysis by Genpathway. Additional information about Illumina’s Sequencing Services with Genpathway’s ChIP assays and data-analysis services can be accessed at www.illumina.com/ChIPsequencingservices.

“We are delighted to team up with Illumina, a world leader in sequencing, to offer the most powerful and comprehensive ChIP-sequencing services available,” said Mary Harper, Ph.D., Chief Scientific Officer of Genpathway. “One of the top applications for sequencing is ChIP, a notoriously time-consuming and difficult procedure. Combining Genpathway’s expertise in ChIP and data-analysis services with Illumina’s high-throughput next-generation sequencing technology and services provides researchers a faster path to discovery.”

Advertisement